Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 23, 2026, 12:38 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Natural Killer Cell Malignancies Clear all
Completed Phase 1 Interventional

Study of CHOP + Campath for T-Cell, Null Cell, or Natural Killer (NK)-Cell Lymphoma

NCT00161590
View directory record Official record
Conditions
T-Cell Lymphoma, Lymphoma, Non-Hodgkin's
Interventions
CHOP and alemtuzumab
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years and older
Timeline
Started 2004
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 21, 2008 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Phase 1 Interventional

Natural Killer Cell (CYNK-001) IV Infusion or IT Administration in Adults With Recurrent GBM

NCT04489420
View directory record Official record
Conditions
Astrocytoma, Grade IV, Giant Cell Glioblastoma, Glioblastoma Multiforme, Cyclophosphamide, Immunosuppressive Agents, Immunologic Factors, Physiological Effects of Drugs, Molecular Mechanisms of Pharmacological Action, Antiviral Agents, Anti-infective Agents, Analgesics, Non-narcotic, Analgesics, Sensory System Agents, Peripheral Nervous System Agents
Interventions
CYNK001-IV, CYNK001-IT
Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years and older
Enrollment
3 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 9, 2022 · Synced Jul 23, 2026, 12:38 PM EDT
Active, not recruiting Phase 1 Interventional Results available

CD19.CAR Allogeneic NKT for Patients With Relapsed or Refractory B-Cell Malignancies (ANCHOR)

NCT03774654
View directory record Official record
Conditions
Refractory B-Cell Non-Hodgkin Lymphoma, Refractory B-Cell Small Lymphocytic Lymphoma, Relapsed Adult ALL, Relapsed CLL, Relapsed Non Hodgkin Lymphoma
Interventions
CD19.CAR-aNKT cells
Genetic
Lead sponsor
Baylor College of Medicine
Other
Eligibility
3 Years to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2040
U.S. locations
2
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Jul 23, 2026, 12:38 PM EDT
Recruiting Phase 2 Interventional

Haploidentical Donor Cytokine-Induced Memory-Like Natural Killer Cells (CIML-NK) for Relapsed & Refractory Neuroblastoma

NCT07635056
View directory record Official record
Conditions
Neuroblastoma
Interventions
CIML-NK Cells
Biological
Lead sponsor
Children's Hospital Medical Center, Cincinnati
Other
Eligibility
1 Year to 39 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 8, 2026 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Phase 1Phase 2 Interventional

CYNK-101 in Combination with Trastuzumab and Pembrolizumab in Patients with Locally Advanced Unresectable or Metastatic HER2-Positive Gastric or Gastroesophageal Junction (G/GEJ) Adenocarcinoma

NCT05207722
View directory record Official record
Conditions
Metastatic HER2 Positive Gastroesophageal Junction Cancer
Interventions
CYNK-101, Pembrolizumab, Trastuzumab, Recombinant Human Interleukin-2, Cyclophosphamide, Fludarabine, Mesna
Biological · Drug
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
3
States / cities
La Jolla, California • Washington D.C., District of Columbia • Hackensack, New Jersey
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 23, 2026, 12:38 PM EDT
Completed Phase 1 Interventional

Combination Chemotherapy, Monoclonal Antibody, and Natural Killer Cells in Treating Young Patients With Recurrent or Refractory Neuroblastoma

NCT01576692
View directory record Official record
Conditions
Neuroblastoma
Interventions
Humanized anti-GD2 antibody, Chemotherapy, Cytokines, Natural killer cells, CliniMACS
Biological · Drug · Other + 1 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2018
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 14, 2018 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Phase 1 Interventional

Study to Evaluate the Safety and Clinical Activity of UCART123 in Patients With BPDCN

NCT03203369
View directory record Official record
Conditions
Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Interventions
UCART123
Biological
Lead sponsor
Cellectis S.A.
Industry
Eligibility
18 Years to 80 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Jul 23, 2026, 12:38 PM EDT
Not listed Phase 1 Interventional

NK Cells in Cord Blood Transplantation

NCT01619761
View directory record Official record
Conditions
Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Biphenotypic Leukemia, Acute Lymphoblastic Leukemia in Remission, Acute Myeloid Leukemia in Remission, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, ISS Stage II Plasma Cell Myeloma, ISS Stage III Plasma Cell Myeloma, Myelodysplastic Syndrome, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Hodgkin Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Hodgkin Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma, Secondary Acute Myeloid Leukemia, Therapy-Related Acute Myeloid Leukemia, Therapy-Related Myelodysplastic Syndrome
Interventions
Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Fludarabine Phosphate, Laboratory Biomarker Analysis, Lenalidomide, Melphalan, Mycophenolate Mofetil, Natural Killer Cell Therapy, Rituximab, Tacrolimus, Total-Body Irradiation, Umbilical Cord Blood Transplantation
Procedure · Drug · Other + 2 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Up to 75 Years
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 10, 2020 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Phase 1Phase 2 Interventional

IMM60 and Pembrolizumab in Melanoma and NSCLC

NCT05709821
View directory record Official record
Conditions
Non-small Cell Lung Cancer, Melanoma
Interventions
IMM60, Pembrolizumab
Drug
Lead sponsor
iOx Therapeutics
Industry
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
5
States / cities
Los Angeles, California • Boston, Massachusetts • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Phase 2 Interventional Results available

Haploidentical Natural Killer (NK) Cells in Patients With Relapsed or Refractory Neuroblastoma

NCT00698009
View directory record Official record
Conditions
Neuroblastoma
Interventions
Fludarabine, Cyclophosphamide, Natural Killer Cell Infusion, Mesna, Interleukin-2
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 23, 2020 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

QUILT-3.060: NANT Pancreatic Cancer Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With Pancreatic Cancer Who Have Progressed on or After Standard-of-care Therapy

NCT03329248
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
ALT-803, ETBX-011, GI-4000, haNK for infusion, avelumab, bevacizumab, Capecitabine, Cyclophosphamide, Fluorouracil, Leucovorin, nab-Paclitaxel, lovaza, Oxaliplatin, SBRT
Biological · Drug · Procedure
Lead sponsor
ImmunityBio, Inc.
Industry
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
El Segundo, California
Source: ClinicalTrials.gov public record
Updated Dec 11, 2024 · Synced Jul 23, 2026, 12:38 PM EDT
Completed Phase 1 Interventional

Natural Killer Cells and Bortezomib to Treat Cancer

NCT00720785
View directory record Official record
Conditions
Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
Interventions
Bortezomib, NK cells
Drug · Biological
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
18 Years to 70 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Jul 23, 2026, 12:38 PM EDT
Completed Phase 1 Interventional

Donor Natural Killer Cells in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

NCT01787474
View directory record Official record
Conditions
Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Myeloid Leukemia
Interventions
Cytarabine, Filgrastim, Filgrastim-sndz, Fludarabine Phosphate, Laboratory Biomarker Analysis, Membrane-bound Interleukin-21-Expanded Haploidentical Natural Killer Cells
Drug · Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Jul 23, 2026, 12:38 PM EDT
Completed Phase 2 Interventional Results available

HLA-Nonidentical Stem Cell and Natural Killer Cell Transplantation for Children Less the Two Years of Age With Hematologic Malignancies

NCT00145626
View directory record Official record
Conditions
Acute Myeloid Leukemia, Acute Lymphocytic Leukemia, Myelodysplasia, Chronic Myeloid Leukemia, Histiocytosis
Interventions
Chemotherapy and antibodies, Miltenyi Biotec CliniMACS, Allogeneic stem cell transplantation
Drug · Device · Procedure
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 24 Months
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jun 18, 2017 · Synced Jul 23, 2026, 12:38 PM EDT
Completed Phase 1 Interventional

A Safety Study of Human Cord Blood Derived, Culture-expanded, Natural Killer Cell (PNK-007) Infusion With or Without Subcutaneous Recombinant Human Interleukin-2 (rhIL-2) Following Autologous Stem Cell Transplant for Multiple Myeloma (MM)

NCT02955550
View directory record Official record
Conditions
Multiple Myeloma
Interventions
rhIL-2, PNK-007
Drug · Biological
Lead sponsor
Celularity Incorporated
Industry
Eligibility
18 Years to 70 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
7
States / cities
Minneapolis, Minnesota • St Louis, Missouri • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Not applicable Interventional Results available

CD3/CD19 Depleted or CD3 Depleted/CD56 Selected Haploidentical Donor Natural Killer (NK) Cell Based Therapy for AML Patients Not in CR

NCT03152526
View directory record Official record
Conditions
Acute Myelogenous Leukemia
Interventions
Interventions
Device
Lead sponsor
Miltenyi Biotec B.V. & Co. KG
Industry
Eligibility
18 Years to 75 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
3
States / cities
Chicago, Illinois • Minneapolis, Minnesota • Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 8, 2020 · Synced Jul 23, 2026, 12:38 PM EDT
Completed Phase 2 Interventional Results available

Penostatin, Rituximab and Ontak and Allogeneic Natural Killer (NK) Cells for Refractory Lymphoid Malignancies

NCT01181258
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia
Interventions
Rituximab, Interleukin-2, Natural killer cells, Cyclophosphamide, Methylprednisolone, Fludarabine
Drug · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Not listed
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2016
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Feb 5, 2018 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Phase 2 Interventional Results available

Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)

NCT00941928
View directory record Official record
Conditions
Leukemia, Pediatric Cancer
Interventions
Epratuzumab, Fludarabine, Cyclophosphamide, Mesna, Infusion of NK cells, Interleukin-2
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Not listed
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 23, 2026, 12:38 PM EDT
Completed Phase 3 Interventional Results available

Clofarabine Plus Cytarabine Versus Conventional Induction Therapy And A Study Of NK Cell Transplantation In Newly Diagnosed Acute Myeloid Leukemia

NCT00703820
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
Cytarabine, Daunorubicin, Etoposide, Clofarabine, CliniMACS
Drug · Device
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
324 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
7
States / cities
Palo Alto, California • San Diego, California • Chicago, Illinois + 4 more
Source: ClinicalTrials.gov public record
Updated Aug 9, 2021 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Not applicable Interventional Results available

Reduced Intensity Conditioning and Haploidentical Related Bone Marrow for Patients With Hematologic Diseases

NCT02145039
View directory record Official record
Conditions
Acute Leukemias, Burkitt's Lymphoma, Chronic Myelogenous Leukemia
Interventions
Fludarabine, Cyclophosphamide, Total Body Irradiation, Haploidentical stem cell transplant
Drug · Radiation · Biological
Lead sponsor
Masonic Cancer Center, University of Minnesota
Other
Eligibility
Up to 74 Years
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 25, 2019 · Synced Jul 23, 2026, 12:38 PM EDT
Withdrawn Phase 1 Interventional

ALT-801-activated Natural Killer Cells After FLAG Induction for Acute Myeloid Leukemia

NCT01478074
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
G-CSF, Cytarabine, Fludarabine, Donor Natural Killer (NK) cells, ALT-801
Drug · Biological
Lead sponsor
Altor BioScience
Industry
Eligibility
2 Years to 59 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2013
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 2, 2014 · Synced Jul 23, 2026, 12:38 PM EDT
Recruiting Phase 1Phase 2 Interventional

Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

NCT06026657
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Gemcitabine, Magnetic Resonance Imaging, Naxitamab, Universal Donor Expanded TGF-beta-imprinted NK Cells
Procedure · Drug · Biological
Lead sponsor
Margaret Gatti-Mays
Other
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Evaluation of Safety and Efficacy of Allo GDA-201 Natural Killer (NK) Cells in Patients With Relapsed/Refractory B Cell NHL

NCT05296525
View directory record Official record
Conditions
Non-Hodgkin Lymphoma
Interventions
GDA-201
Drug
Lead sponsor
Gamida Cell ltd
Industry
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
6
States / cities
Jacksonville, Florida • Maywood, Illinois • Boston, Massachusetts + 3 more
Source: ClinicalTrials.gov public record
Updated Mar 24, 2025 · Synced Jul 23, 2026, 12:38 PM EDT
Terminated Phase 2 Interventional Results available

Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation

NCT02259348
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia (ALL), Acute Myeloid Leukemia (AML), Myeloid Sarcoma, Chronic Myelogenous Leukemia (CML), Juvenile Myelomonocytic Leukemia (JMML), Myelodysplastic Syndrome (MDS), Non-Hodgkin Lymphoma (NHL)
Interventions
Cyclophosphamide, Fludarabine, G-CSF, Interleukin-2, Melphalan, Thiotepa, Rituximab, Natural killer cell therapy, T-cell depleted HPC transplant, CD45RA-depleted HPC transplant
Drug · Biological
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 21 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated May 29, 2017 · Synced Jul 23, 2026, 12:38 PM EDT